Published in J Biol Chem on September 18, 2013
Structural determinants of integrin β-subunit specificity for latent TGF-β. Nat Struct Mol Biol (2014) 0.97
Metal ion and ligand binding of integrin α5β1. Proc Natl Acad Sci U S A (2014) 0.96
Anti-α4 antibody treatment blocks virus traffic to the brain and gut early, and stabilizes CNS injury late in infection. PLoS Pathog (2014) 0.92
Role of integrin alpha4 in drug resistance of leukemia. Front Oncol (2014) 0.88
Pathway-based approaches to the treatment of inflammatory bowel disease. Transl Res (2015) 0.83
Anti-α4 Integrin Antibody Blocks Monocyte/Macrophage Traffic to the Heart and Decreases Cardiac Pathology in a SIV Infection Model of AIDS. J Am Heart Assoc (2015) 0.80
Macrophage Polarization in AIDS: Dynamic Interface between Anti-Viral and Anti-Inflammatory Macrophages during Acute and Chronic Infection. J Clin Cell Immunol (2015) 0.79
Canonical structures of short CDR-L3 in antibodies. Proteins (2014) 0.79
New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies. J Neuroinflammation (2016) 0.79
Epitopes in α8β1 and other RGD-binding integrins delineate classes of integrin-blocking antibodies and major binding loops in α subunits. Sci Rep (2015) 0.78
Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor. PLoS One (2015) 0.77
Systematic screening of soluble expression of antibody fragments in the cytoplasm of E. coli. Microb Cell Fact (2016) 0.76
Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets. Clin Exp Gastroenterol (2016) 0.76
Ligand-induced Epitope Masking: DISSOCIATION OF INTEGRIN α5β1-FIBRONECTIN COMPLEXES ONLY BY MONOCLONAL ANTIBODIES WITH AN ALLOSTERIC MODE OF ACTION. J Biol Chem (2016) 0.75
Glycosylation and oligomeric state of envelope protein might influence HIV-1 virion capture by α4β7 integrin. Virology (2017) 0.75
Integrins as Therapeutic Targets: Successes and Cancers. Cancers (Basel) (2017) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
Phaser crystallographic software. J Appl Crystallogr (2007) 108.34
PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr (2002) 53.61
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res (2007) 37.31
Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell (1994) 27.85
Linking crystallographic model and data quality. Science (2012) 12.13
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 11.29
Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature (1992) 7.20
Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc Natl Acad Sci U S A (2002) 5.91
Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature (2004) 5.87
G protein-coupled receptor allosterism and complexing. Pharmacol Rev (2002) 5.01
AL2CO: calculation of positional conservation in a protein sequence alignment. Bioinformatics (2001) 4.79
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology (2007) 3.32
Folding of the N-terminal, ligand-binding region of integrin alpha-subunits into a beta-propeller domain. Proc Natl Acad Sci U S A (1997) 2.27
Functional evidence for three distinct and independently inhibitable adhesion activities mediated by the human integrin VLA-4. Correlation with distinct alpha 4 epitopes. J Biol Chem (1991) 2.17
Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med (2003) 1.90
Integrin inside-out signaling and the immunological synapse. Curr Opin Cell Biol (2011) 1.89
Fibronectin promotes proliferation of naive and memory T cells by signaling through both the VLA-4 and VLA-5 integrin molecules. J Immunol (1990) 1.83
The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther (2009) 1.73
Allosteric beta1 integrin antibodies that stabilize the low affinity state by preventing the swing-out of the hybrid domain. J Biol Chem (2004) 1.60
Crystal structure of an integrin-binding fragment of vascular cell adhesion molecule-1 at 1.8 A resolution. Nature (1995) 1.55
Crystal structure of α5β1 integrin ectodomain: atomic details of the fibronectin receptor. J Cell Biol (2012) 1.52
Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff equations. Br J Pharmacol (1993) 1.49
Functional and structural stability of the epidermal growth factor receptor in detergent micelles and phospholipid nanodiscs. Biochemistry (2008) 1.48
Regulation of integrin affinity on cell surfaces. EMBO J (2011) 1.47
Residues within a conserved amino acid motif of domains 1 and 4 of VCAM-1 are required for binding to VLA-4. J Cell Biol (1994) 1.43
Structural principles for the propeller assembly of beta-sheets: the preference for seven-fold symmetry. Proteins (1992) 1.38
Requirement of open headpiece conformation for activation of leukocyte integrin alphaXbeta2. Proc Natl Acad Sci U S A (2010) 1.32
Identification of putative ligand-binding sites of the integrin alpha 4 beta 1 (VLA-4, CD49d/CD29) Biochem J (1995) 1.32
Beta1 integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunity. Proc Natl Acad Sci U S A (2009) 1.27
Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology (2011) 1.24
Alpha4beta1 integrin affinity changes govern cell adhesion. J Biol Chem (2003) 1.20
A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol (1995) 1.20
Critical amino acid residues for ligand binding are clustered in a predicted beta-turn of the third N-terminal repeat in the integrin alpha 4 and alpha 5 subunits. EMBO J (1995) 1.18
Efalizumab binding to the LFA-1 alphaL I domain blocks ICAM-1 binding via steric hindrance. Proc Natl Acad Sci U S A (2009) 1.13
Structural specializations of α(4)β(7), an integrin that mediates rolling adhesion. J Cell Biol (2012) 1.13
Alpha4 integrin binding interfaces on VCAM-1 and MAdCAM-1. Integrin binding footprints identify accessory binding sites that play a role in integrin specificity. J Biol Chem (1997) 1.11
Molecular mapping of functional antibody binding sites of alpha 4 integrin. J Biol Chem (1995) 1.08
Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies (1997) 1.00
Domains 1 and 4 of vascular cell adhesion molecule-1 (CD106) both support very late activation antigen-4 (CD49d/CD29)-dependent monocyte transendothelial migration. J Immunol (1995) 0.91
Similar but nonidentical amino acid residues on vascular cell adhesion molecule-1 are involved in the interaction with alpha 4 beta 1 and alpha 4 beta 7 under different activity states. J Immunol (1995) 0.90
A novel Ca2+ binding beta hairpin loop better resembles integrin sequence motifs than the EF hand. Cell (2000) 0.87
Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri®) with endogenous IgG4. J Pharm Biomed Anal (2011) 0.87
Antibodies for all: The case for genome-wide affinity reagents. FEBS Lett (2012) 0.86
The cost effectiveness and budget impact of natalizumab for formulary inclusion. J Med Econ (2010) 0.83
Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. J Med Econ (2011) 0.82
Structure of a functional fragment of VCAM-1 refined at 1.9 a resolution. Acta Crystallogr D Biol Crystallogr (1996) 0.79
Structural basis of integrin regulation and signaling. Annu Rev Immunol (2007) 8.60
Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell (2002) 7.03
Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature (2004) 5.87
Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science (2003) 5.58
The genome of M. acetivorans reveals extensive metabolic and physiological diversity. Genome Res (2002) 4.58
Transcellular diapedesis is initiated by invasive podosomes. Immunity (2007) 4.06
Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science (2009) 3.85
Conformational regulation of integrin structure and function. Annu Rev Biophys Biomol Struct (2001) 3.74
A transmigratory cup in leukocyte diapedesis both through individual vascular endothelial cells and between them. J Cell Biol (2004) 3.66
Integrin avidity regulation: are changes in affinity and conformation underemphasized? Curr Opin Cell Biol (2003) 3.59
Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forces. Mol Cell (2008) 3.54
Latent TGF-β structure and activation. Nature (2011) 3.42
RIAM, an Ena/VASP and Profilin ligand, interacts with Rap1-GTP and mediates Rap1-induced adhesion. Dev Cell (2004) 3.27
Activation of leukocyte beta2 integrins by conversion from bent to extended conformations. Immunity (2006) 3.11
Structure of integrin alpha5beta1 in complex with fibronectin. EMBO J (2003) 2.99
Integrin activation and structural rearrangement. Immunol Rev (2002) 2.60
Cysteine-rich module structure reveals a fulcrum for integrin rearrangement upon activation. Nat Struct Biol (2002) 2.56
Conversion between three conformational states of integrin I domains with a C-terminal pull spring studied with molecular dynamics. Structure (2004) 2.35
Small molecule integrin antagonists that bind to the beta2 subunit I-like domain and activate signals in one direction and block them in the other. Immunity (2003) 2.34
A specific interface between integrin transmembrane helices and affinity for ligand. PLoS Biol (2004) 2.26
The primacy of affinity over clustering in regulation of adhesiveness of the integrin {alpha}L{beta}2. J Cell Biol (2004) 2.22
Integrin structures and conformational signaling. Curr Opin Cell Biol (2006) 2.03
Archaeal surface layer proteins contain beta propeller, PKD, and beta helix domains and are related to metazoan cell surface proteins. Structure (2002) 2.00
Rolling adhesion through an extended conformation of integrin alphaLbeta2 and relation to alpha I and beta I-like domain interaction. Immunity (2004) 1.98
Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov (2003) 1.98
Endothelial cells proactively form microvilli-like membrane projections upon intercellular adhesion molecule 1 engagement of leukocyte LFA-1. J Immunol (2003) 1.95
Stabilizing the open conformation of the integrin headpiece with a glycan wedge increases affinity for ligand. Proc Natl Acad Sci U S A (2003) 1.93
Bistable regulation of integrin adhesiveness by a bipolar metal ion cluster. Nat Struct Biol (2003) 1.92
Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor. Proc Natl Acad Sci U S A (2009) 1.91
A mechanically stabilized receptor-ligand flex-bond important in the vasculature. Nature (2010) 1.90
Importance of force linkage in mechanochemistry of adhesion receptors. Biochemistry (2006) 1.87
The structure of a receptor with two associating transmembrane domains on the cell surface: integrin alphaIIbbeta3. Mol Cell (2009) 1.82
Nonmuscle myosin heavy chain IIA mediates integrin LFA-1 de-adhesion during T lymphocyte migration. J Exp Med (2008) 1.76
Remodeling of the lectin-EGF-like domain interface in P- and L-selectin increases adhesiveness and shear resistance under hydrodynamic force. Nat Immunol (2006) 1.74
Disrupting integrin transmembrane domain heterodimerization increases ligand binding affinity, not valency or clustering. Proc Natl Acad Sci U S A (2005) 1.73
Structure of an integrin with an alphaI domain, complement receptor type 4. EMBO J (2009) 1.70
Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor. Mol Cell Biol (2010) 1.63
Complex between nidogen and laminin fragments reveals a paradigmatic beta-propeller interface. Nature (2003) 1.61
Allosteric beta1 integrin antibodies that stabilize the low affinity state by preventing the swing-out of the hybrid domain. J Biol Chem (2004) 1.60
Structural transitions of complement component C3 and its activation products. Proc Natl Acad Sci U S A (2006) 1.57
Locking the beta3 integrin I-like domain into high and low affinity conformations with disulfides. J Biol Chem (2003) 1.56
Requirement of alpha and beta subunit transmembrane helix separation for integrin outside-in signaling. Blood (2007) 1.52
Intersubunit signal transmission in integrins by a receptor-like interaction with a pull spring. Proc Natl Acad Sci U S A (2004) 1.49
Functional and structural stability of the epidermal growth factor receptor in detergent micelles and phospholipid nanodiscs. Biochemistry (2008) 1.48
Regulation of integrin affinity on cell surfaces. EMBO J (2011) 1.47
Role for CCR7 ligands in the emigration of newly generated T lymphocytes from the neonatal thymus. Immunity (2002) 1.46
Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor. Nat Struct Mol Biol (2011) 1.45
Highly reinforced structure of a C-terminal dimerization domain in von Willebrand factor. Blood (2014) 1.44
Trans-cellular migration: cell-cell contacts get intimate. Curr Opin Cell Biol (2008) 1.42
Two-dimensional kinetics regulation of alphaLbeta2-ICAM-1 interaction by conformational changes of the alphaL-inserted domain. J Biol Chem (2005) 1.38
Complete integrin headpiece opening in eight steps. J Cell Biol (2013) 1.37
Integrin beta3 regions controlling binding of murine mAb 7E3: implications for the mechanism of integrin alphaIIbbeta3 activation. Proc Natl Acad Sci U S A (2004) 1.36
Activation of integrin beta-subunit I-like domains by one-turn C-terminal alpha-helix deletions. Proc Natl Acad Sci U S A (2004) 1.35
A pH-regulated dimeric bouquet in the structure of von Willebrand factor. EMBO J (2011) 1.34
Requirement of open headpiece conformation for activation of leukocyte integrin alphaXbeta2. Proc Natl Acad Sci U S A (2010) 1.32
Directed evolution to probe protein allostery and integrin I domains of 200,000-fold higher affinity. Proc Natl Acad Sci U S A (2006) 1.32
An atomic resolution view of ICAM recognition in a complex between the binding domains of ICAM-3 and integrin alphaLbeta2. Proc Natl Acad Sci U S A (2005) 1.30
Closed headpiece of integrin αIIbβ3 and its complex with an αIIbβ3-specific antagonist that does not induce opening. Blood (2010) 1.29
Tests of the extension and deadbolt models of integrin activation. J Biol Chem (2007) 1.28
GARP regulates the bioavailability and activation of TGFβ. Mol Biol Cell (2012) 1.28
The critical cytoplasmic regions of the alphaL/beta2 integrin in Rap1-induced adhesion and migration. Mol Biol Cell (2003) 1.26
Sequence and structure relationships within von Willebrand factor. Blood (2012) 1.26
Rational design of intercellular adhesion molecule-1 (ICAM-1) variants for antagonizing integrin lymphocyte function-associated antigen-1-dependent adhesion. J Biol Chem (2005) 1.24
Exposure of acidic residues as a danger signal for recognition of fibrinogen and other macromolecules by integrin alphaXbeta2. Proc Natl Acad Sci U S A (2005) 1.24
Structural basis for dimerization of ICAM-1 on the cell surface. Mol Cell (2004) 1.24
AL-57, a ligand-mimetic antibody to integrin LFA-1, reveals chemokine-induced affinity up-regulation in lymphocytes. Proc Natl Acad Sci U S A (2006) 1.20
Structure and allosteric regulation of the alpha X beta 2 integrin I domain. Proc Natl Acad Sci U S A (2003) 1.18
Stabilizing the integrin alpha M inserted domain in alternative conformations with a range of engineered disulfide bonds. Proc Natl Acad Sci U S A (2002) 1.18
The binding sites for competitive antagonistic, allosteric antagonistic, and agonistic antibodies to the I domain of integrin LFA-1. J Immunol (2004) 1.18
Unexpected fold in the circumsporozoite protein target of malaria vaccines. Proc Natl Acad Sci U S A (2012) 1.14
Activation-induced conformational changes in the I domain region of lymphocyte function-associated antigen 1. J Biol Chem (2002) 1.14
The relative influence of metal ion binding sites in the I-like domain and the interface with the hybrid domain on rolling and firm adhesion by integrin alpha4beta7. J Biol Chem (2004) 1.13
Structural specializations of α(4)β(7), an integrin that mediates rolling adhesion. J Cell Biol (2012) 1.13
The role of the specificity-determining loop of the integrin beta subunit I-like domain in autonomous expression, association with the alpha subunit, and ligand binding. Biochemistry (2002) 1.13
Molecular basis for interaction between Icap1 alpha PTB domain and beta 1 integrin. J Biol Chem (2001) 1.12
Transition from rolling to firm adhesion can be mimicked by extension of integrin alphaLbeta2 in an intermediate affinity state. J Biol Chem (2006) 1.12
Transmission of allostery through the lectin domain in selectin-mediated cell adhesion. Proc Natl Acad Sci U S A (2008) 1.12
The integrin alpha-subunit leg extends at a Ca2+-dependent epitope in the thigh/genu interface upon activation. Proc Natl Acad Sci U S A (2004) 1.11
Regulation of outside-in signaling and affinity by the beta2 I domain of integrin alphaLbeta2. Proc Natl Acad Sci U S A (2006) 1.10
Chondroitin sulfate B exerts its inhibitory effect on secondary lymphoid tissue chemokine (SLC) by binding to the C-terminus of SLC. Biochim Biophys Acta (2002) 1.08
Structure-guided design of a high-affinity platelet integrin αIIbβ3 receptor antagonist that disrupts Mg²⁺ binding to the MIDAS. Sci Transl Med (2012) 1.07
Intact alphaIIbbeta3 integrin is extended after activation as measured by solution X-ray scattering and electron microscopy. J Biol Chem (2011) 1.07
A novel calcium-binding site of von Willebrand factor A2 domain regulates its cleavage by ADAMTS13. Blood (2011) 1.06
Contribution of N-linked glycans to the conformation and function of intercellular adhesion molecules (ICAMs). J Biol Chem (2004) 1.05
Modulation of integrin activation by an entropic spring in the {beta}-knee. J Biol Chem (2010) 1.05
A small molecule agonist of an integrin, alphaLbeta2. J Biol Chem (2006) 1.04
Antigen recognition is facilitated by invadosome-like protrusions formed by memory/effector T cells. J Immunol (2012) 1.04
Release of cellular tension signals self-restorative ventral lamellipodia to heal barrier micro-wounds. J Cell Biol (2013) 1.03
Calcium stabilizes the von Willebrand factor A2 domain by promoting refolding. Proc Natl Acad Sci U S A (2012) 1.02
α(V)β(3) integrin crystal structures and their functional implications. Biochemistry (2012) 1.02
Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor. J Biol Chem (2012) 1.01
An unusual allosteric mobility of the C-terminal helix of a high-affinity alphaL integrin I domain variant bound to ICAM-5. Mol Cell (2008) 1.01
Rationally designed integrin beta3 mutants stabilized in the high affinity conformation. J Biol Chem (2008) 1.00
Specific and covalent labeling of a membrane protein with organic fluorochromes and quantum dots. Proc Natl Acad Sci U S A (2007) 0.99
N-glycan structures and N-glycosylation sites of mouse soluble intercellular adhesion molecule-1 revealed by MALDI-TOF and FTICR mass spectrometry. Glycobiology (2006) 0.98
Boca-dependent maturation of beta-propeller/EGF modules in low-density lipoprotein receptor proteins. EMBO J (2004) 0.98
Identification and characterization of a human monoclonal antagonistic antibody AL-57 that preferentially binds the high-affinity form of lymphocyte function-associated antigen-1. J Leukoc Biol (2006) 0.98
An internal ligand-bound, metastable state of a leukocyte integrin, αXβ2. J Cell Biol (2013) 0.98
Structural basis of regulation of von Willebrand factor binding to glycoprotein Ib. J Biol Chem (2014) 0.97